• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Philip Morris International Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    12/11/25 4:07:59 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    false 0001413329 0001413329 2025-12-11 2025-12-11 0001413329 us-gaap:CommonStockMember 2025-12-11 2025-12-11 0001413329 pm:Notes2.750PercentDue2026Member 2025-12-11 2025-12-11 0001413329 pm:NotesDue2.875Percent2026Member 2025-12-11 2025-12-11 0001413329 pm:Notes0.125PercentDue2026Member 2025-12-11 2025-12-11 0001413329 pm:Notes3.125PercentDue2027Member 2025-12-11 2025-12-11 0001413329 pm:Notes3.125PercentDue2028Member 2025-12-11 2025-12-11 0001413329 pm:Notes2.875PercentDue2029Member 2025-12-11 2025-12-11 0001413329 pm:Notes3.375PercentDue2029Member 2025-12-11 2025-12-11 0001413329 pm:Notes2.750PercentDue2029Member 2025-12-11 2025-12-11 0001413329 pm:Notes3.750PercentDue2031Member 2025-12-11 2025-12-11 0001413329 pm:Notes0.800PercentDue2031Member 2025-12-11 2025-12-11 0001413329 pm:Notes3.250PercentDue2032Member 2025-12-11 2025-12-11 0001413329 pm:Notes3.125PercentDue2033Member 2025-12-11 2025-12-11 0001413329 pm:Notes2.000PercentDue2036Member 2025-12-11 2025-12-11 0001413329 pm:Notes1.875PercentDue2037Member 2025-12-11 2025-12-11 0001413329 pm:Notes6.375PercentDue2038Member 2025-12-11 2025-12-11 0001413329 pm:Notes1.450PercentDue2039Member 2025-12-11 2025-12-11 0001413329 pm:Notes4.375PercentDue2041Member 2025-12-11 2025-12-11 0001413329 pm:Notes4.500PercentDue2042Member 2025-12-11 2025-12-11 0001413329 pm:Notes3.875PercentDue2042Member 2025-12-11 2025-12-11 0001413329 pm:Notes4.125PercentDue2043Member 2025-12-11 2025-12-11 0001413329 pm:Notes4.875PercentDue2043Member 2025-12-11 2025-12-11 0001413329 pm:Notes4.250PercentDue2044Member 2025-12-11 2025-12-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 11, 2025

     

     

    Philip Morris International Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Virginia 1-33708 13-3435103

    (State or other jurisdiction

    of incorporation)

    (Commission File Number)

    (I.R.S. Employer

    Identification No.)

     

    677 Washington Blvd, Suite 1100

    Stamford, Connecticut

    06901
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (203) 905-2410

     

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, no par value   PM   New York Stock Exchange
    2.750% Notes due 2026   PM26A   New York Stock Exchange
    2.875% Notes due 2026   PM26   New York Stock Exchange
    0.125% Notes due 2026   PM26B   New York Stock Exchange
    3.125% Notes due 2027   PM27   New York Stock Exchange
    3.125% Notes due 2028   PM28   New York Stock Exchange
    2.875% Notes due 2029   PM29   New York Stock Exchange
    3.375% Notes due 2029   PM29A   New York Stock Exchange
    2.750% Notes due 2029   PM29D   New York Stock Exchange
    3.750% Notes due 2031   PM31B   New York Stock Exchange
    0.800% Notes due 2031   PM31   New York Stock Exchange
    3.250% Notes due 2032   PM32   New York Stock Exchange
    3.125% Notes due 2033   PM33   New York Stock Exchange
    2.000% Notes due 2036   PM36   New York Stock Exchange
    1.875% Notes due 2037   PM37A   New York Stock Exchange
    6.375% Notes due 2038   PM38   New York Stock Exchange
    1.450% Notes due 2039   PM39   New York Stock Exchange
    4.375% Notes due 2041   PM41   New York Stock Exchange
    4.500% Notes due 2042   PM42   New York Stock Exchange
    3.875% Notes due 2042   PM42A   New York Stock Exchange
    4.125% Notes due 2043   PM43   New York Stock Exchange
    4.875% Notes due 2043   PM43A   New York Stock Exchange
    4.250% Notes due 2044   PM44   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On December 11, 2025, Philip Morris International Inc. (“PMI”) entered into a credit agreement, effective as of January 29, 2026 (the “Credit Agreement”), relating to a senior unsecured revolving credit facility (the “Facility”) with the lenders named therein, Citibank Europe plc, UK Branch, as facility agent, and Citibank, N.A., as swingline agent. The Facility provides for borrowings up to an aggregate principal amount of US$2.0 billion (or the equivalent in Euro) and expires on January 29, 2031, unless extended as further described in the Credit Agreement.

     

    Interest rates on borrowings under the Facility will be based on prevailing interest rates for U.S. Dollars or Euro, as applicable, and as further described in the Credit Agreement. The Facility will be used for general corporate purposes, including to meet working capital requirements.

     

    The Credit Agreement contains certain events of default customary for credit facilities of this type (with customary grace periods, as applicable), including nonpayment of principal or interest when due; material incorrectness of representations and warranties when made; breach of covenants; bankruptcy and insolvency; unsatisfied ERISA obligations; unstayed material judgment beyond specified periods; acceleration or payment default of other material indebtedness; and invalidation of PMI’s guaranty of subsidiary borrowings.

     

    If any events of default occur and are not cured within applicable grace periods or waived, any outstanding loans may be accelerated and the lenders’ commitments may be terminated. The occurrence of a bankruptcy and insolvency event of default will result in the automatic termination of commitments and acceleration of outstanding loans under the Credit Agreement.

     

    The Facility will replace PMI’s existing US$2.0 billion (or the equivalent in Euro) revolving credit facility with the lenders named therein, Citibank Europe plc, UK Branch, as facility agent, and Citibank, N.A., as swingline agent, which was to expire on February 10, 2027 (the “Terminating Facility”). PMI provided notice of termination of the Terminating Facility on December 11, 2025, with termination effective as of January 29, 2026, conditional upon the effectiveness of the Credit Agreement.

     

    At December 11, 2025, PMI had no borrowings outstanding under the Terminating Facility.

     

    On December 11, 2025, PMI also entered into an agreement, effective as of January 29, 2026 (the “Amendment and Extension Agreement”), to amend and extend the term of its existing €1.5 billion revolving credit facility, dated December 17, 2024 (the “2024 Credit Agreement”) with the lenders named therein and Citibank Europe plc, UK Branch, as facility agent. The Amendment and Extension Agreement extends the expiration date of the 2024 Credit Agreement from January 29, 2028 to January 29, 2029, pursuant to Section 2.20 of the 2024 Credit Agreement, and provides for certain other amendments to the Credit Agreement.

     

    Except as set forth in the Amendment and Extension Agreement, all the other terms and conditions of the 2024 Credit Agreement remain in full force and effect.

     

    Certain of the lenders under each of the Credit Agreement and the 2024 Credit Agreement and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory, commercial and investment banking services for PMI, for which they received or will receive customary fees and expenses. Certain affiliates of the lenders are underwriters of certain of PMI’s note issuances. PMI and some of its subsidiaries may enter into foreign exchange and other derivative arrangements with certain of the lenders and their affiliates. In addition, certain of the lenders and their respective affiliates act as dealers in connection with PMI’s commercial paper programs.

     

    The descriptions above of the Credit Agreement and the Amendment and Extension Agreement are summaries and are qualified in their entirety by the Credit Agreement, which is filed as Exhibit 10.1 to this report, and the Amendment and Extension Agreement, which is filed as Exhibit 10.2 to this report, respectively, and each are incorporated herein by reference.

     

    Item 1.02. Termination of a Material Definitive Agreement.

     

    The information set forth above under Item 1.01 regarding the Terminating Facility is hereby incorporated by reference into this Item 1.02.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information required by Item 2.03 and included under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

     

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    Number
      Description
         
    10.1   Credit Agreement, dated December 11, 2025, among Philip Morris International Inc., the lenders named therein, Citibank Europe plc, UK Branch, as facility agent, and Citibank, N.A., as swingline agent
         
    10.2   Amendment and Extension Agreement, dated December 11, 2025, among Philip Morris International Inc., the lenders named therein and Citibank Europe plc, UK Branch, as facility agent
         
    104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document and contained in Exhibit 101)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    PHILIP MORRIS INTERNATIONAL INC.
      
    By: /s/ DARLENE QUASHIE HENRY
    Name: Darlene Quashie Henry
    Title: Vice President, Associate General Counsel and Corporate Secretary

     

    DATE: December 11, 2025

     

     

     

    Get the next $PM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    More analyst ratings

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FERRARI RENEWS ITS PARTNERSHIP WITH PHILIP MORRIS INTERNATIONAL

    Maranello (Italy), December 3, 2025 – Ferrari N.V. (NYSE/EXM: RACE) ("Ferrari" or "the Company") announced today that Ferrari S.p.A., its wholly-owned Italian subsidiary, has renewed and strengthened its multi-year partnership with Philip Morris International (NYSE:PM). Under the agreement – signed today and taking effect on January 1, 2026 – Philip Morris International becomes a Premium Partner of Scuderia Ferrari HP and a Series Partner of the Ferrari Challenge Trofeo Pirelli, continuing a collaboration that has spanned more than 50 years.  For further information:Media Relationstel.: +39 0536 949337Email: [email protected] Attachment CS_FNV_PMI_ENG

    12/3/25 6:19:09 AM ET
    $PM
    $RACE
    Medicinal Chemicals and Botanical Products
    Health Care
    Auto Manufacturing
    Industrials

    Philip Morris International Expands its Partnership with Scuderia Ferrari HP, Launching a Bold New Chapter in Their Long-Standing Relationship

    ZYN Branding to be present in selected races, starting with the Formula 1 Etihad Airways Abu Dhabi Grand Prix 2025 Philip Morris International Inc. (NYSE:PM) today announced an expanded partnership with Scuderia Ferrari HP and with Ferrari Challenge Trofeo Pirelli—the single-marque motorsport championship created in 1993—for the 2026 season and beyond. This next chapter introduces one major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally1—will feature on Scuderia Ferrari HP Formula 1 liveries at select races throughout the seasons. This bold new chapter reinforces a spirit of relentless innovation and unforgettable experiences that has defined t

    12/3/25 6:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Presents at 2025 Morgan Stanley Global Consumer & Retail Conference

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) Chief Executive Officer, Jacek Olczak, will address investors today at the Morgan Stanley Global Consumer & Retail Conference. The event will be webcast live in listen-only mode here, beginning at approximately 10:15 a.m. ET, and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for six months after the event. 2025 Full-Year Forecast PMI reaffirms its 2025 full-year reported diluted EPS forecast, announced on October 21, 2025, of $7.39 to $7.49. Excluding a total 2025 adjustment of $0.07 per share, this forecast represents a projected increase of 13.5% t

    12/2/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Trumpaitis Mindaugas claimed ownership of 73,002 shares (SEC Form 3)

    3 - Philip Morris International Inc. (0001413329) (Issuer)

    6/9/25 3:34:30 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Temperley Dessislava was granted 1,002 shares, increasing direct ownership by 15% to 7,756 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:43 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Bough Bonin was granted 1,002 shares, increasing direct ownership by 11% to 9,834 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:34 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $PM
    SEC Filings

    View All

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International upgraded by UBS with a new price target

    UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

    4/25/25 8:25:28 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    12/11/25 4:07:59 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    12/2/25 7:10:48 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Other Events

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    11/17/25 4:08:08 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Presents at 2025 Morgan Stanley Global Consumer & Retail Conference

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) Chief Executive Officer, Jacek Olczak, will address investors today at the Morgan Stanley Global Consumer & Retail Conference. The event will be webcast live in listen-only mode here, beginning at approximately 10:15 a.m. ET, and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for six months after the event. 2025 Full-Year Forecast PMI reaffirms its 2025 full-year reported diluted EPS forecast, announced on October 21, 2025, of $7.39 to $7.49. Excluding a total 2025 adjustment of $0.07 per share, this forecast represents a projected increase of 13.5% t

    12/2/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Third-Quarter & First Nine-Months Results

    Raises Full-Year Adjusted Diluted EPS Guidance and Revises Assumptions; Third-Quarter Reported Diluted EPS Grew 13.2% to $2.23, Adjusted Diluted EPS Grew 17.3% to $2.24, and by 13.1% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 third quarter results.1 "In the third quarter, we continued to invest in the growth of our increasingly profitable smoke-free business, while achieving record quarterly smoke-free gross profit and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "Our global smoke-free portfolio is outgrowing the industry by a clear margin, driving positive total volumes, strong top-line growth an

    10/21/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Increases Dividend by 8.9% to Annualized Rate of $5.88 per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (PMI) (NYSE:PM) has increased the company's regular quarterly dividend by 8.9% to an annualized rate of $5.88 per share. The new quarterly dividend of $1.47 per share, up from $1.35 per share, is payable on October 20, 2025, to shareholders of record as of October 3, 2025. The ex-dividend date is October 3, 2025. PMI has increased its annual dividend every year since becoming a public company in 2008, representing a total increase of 219.6%, or a compound annual growth rate of 7.1%. For additional dividend information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Ph

    9/19/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

    In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

    3/4/24 6:48:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care